Sandoz Outlines Ambitious Biosimilar Growth Strategy with Bio100 Roadmap
At its Capital Markets Day on September 8, Sandoz announced an ambitious growth strategy called 'Bio100,' aiming to expand its biosimilars portfolio from the current 13 products to over 100 by 2040. The company plans to leverage a growing patent cliff and increased loss of exclusivity (LOE) value, which it estimates will triple compared to the last decade. CEO Richard Saynor emphasized that this is an 'unparalleled opportunity' for Sandoz to become the market leader in biosimilars. A key focus area identified by Chief Commercial Officer Rebecca Guntern includes glucagon-like peptide-1 receptor agonists (GLP-1RAs), monoclonal antibodies, and antibody drug conjugates. These modalities are expected to drive significant revenue due to their high LOE value and market growth potential. Sandoz also aims to capture 80% of the LOE value by 2035, targeting over $300 billion in originator sales not currently addressed. The strategy includes both internal development and partnerships as part of its approach to meet rising demand for biosimilars across various therapeutic areas. Sandoz is already marketing Hyrimoz, a biosimilar referencing AbbVie's Humira, which previously generated over $21 billion in annual sales.
